RxDoctor Payments Data

Gladwyn Baptist, MD

Cardiovascular Disease · Bridgeton, NJNPI 1255390944

Payments from drug & device makers

$1,173in general payments, 2019–2025

Across 51 payments — averaging $23.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$288
  • Johnson & Johnson$140
  • Medtronic$132
  • Novartis$101
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$85
  • Merck$67
  • plus $360 from 10 others

What the payments were for

  • Food & beverage$1,15298%
  • Education$222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,173 in reported general payments places this provider in the 30th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$85,033
Medicare patients
697
Services billed
1,369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban45$48,318
EliquisApixaban38$35,824
Metoprolol Succinate121$1,975
Atorvastatin Calcium112$1,699
Digoxin26$905
Midodrine Hcl12$862
ClopidogrelClopidogrel Bisulfate53$853
Carvedilol44$826
Losartan Potassium47$818
Amlodipine Besylate104$758
Warfarin Sodium41$682
Atenolol44$665
Metoprolol Tartrate68$628
Potassium Chloride23$558
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$140$48,31845 claims
PfizerEliquis$288$35,82438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Bridgeton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →